Reviewed by Sahil Chopra, MD.

Research by Savit Malhotra and Theresa Do.

Introduction

As we wrap up our series on heart rate variability and cyclic variation of heart rate, we now shift our focus to a new topic that has gained interest within the sleep community: delta sleep-inducing peptide (DSIP). DSIP is a compound that was initially investigated for its potential role in promoting sleep.[1] Despite ongoing interest, DSIP remains an investigational compound. The U.S Food and Drug Administration (FDA) has not approved DSIP for the treatment of insomnia or any medical condition.[2] As much of the available evidence is limited, the efficacy, safety profile, and clinical applications of DSIP have not been firmly established. In this article, we review the history of DSIP, discuss what researchers currently understand about how it may work, and highlight the limitations of existing research.

The History of Delta Sleep-Inducing Peptide

Scientists have long been interested in understanding why we sleep and what biological signals help regulate this essential process. Beginning in 1963, the Schoenenberger-Monnier research group investigated whether specific compounds circulating in the bloodstream might contribute to the initiation and maintenance of sleep.[1] Their work led to the characterization of DSIP, which was published in 1977 after more than a decade of research.[2] Investigators isolated the peptide from the cerebral venous blood of rabbits that had been induced to sleep through electrical stimulation of a specific brain region called the intralaminar thalamus.[1,2] The peptide consisted of nine amino acids and was named delta sleep-inducing peptide because of its apparent ability to enhance delta-wave activity, a characteristic feature of deep non-rapid eye movement (NREM) sleep.

DSIP showed potential in early animal and small human trials to decrease sleep latency and improve the depth and efficiency of sleep.[3] Early experiments in animal models suggested that the administration of DSIP can increase slow-wave sleep in these models and potentially regulate sleep patterns.[4] Some small human studies reported improvements in sleep efficiency and sleep latency in chronic insomniacs, though the effects were described as weak and not consistently different from placebo.[5] Other human studies by researchers closely associated with DSIP's discovery reported more favorable results, including normalization of disturbed sleep following repeated injections.[6] Additionally, throughout the 1980s, DSIP was also researched for its potential influence on endocrine function, stress response, pain perception, and the effects of drugs such as morphine and amphetamines.[4] 

However, enthusiasm surrounding DSIP was shaken due to difficulties replicating the original findings. While some studies observed sleep-promoting effects, others found minimal or inconsistent changes in sleep architecture following DSIP administration.[3] Interestingly, one study that measured circulating DSIP levels in humans found that levels were actually lowest at night and highest in the afternoon, which was the opposite of what would be expected for a straightforward sleep-promoting factor. Furthermore, researchers were unable to identify the DSIP gene, a precursor protein, or a specific receptor for the peptide.[7] Questions arose whether DSIP truly exists as a naturally occurring peptide in humans or whether the observed activity represented related peptide fragments.[4] Due to these concerns, at present, DSIP remains an experimental compound with ongoing debate regarding its physiological significance. 

How does Delta Sleep-Inducing Peptide Work?

DSIP is specifically a type of compound called a neuropeptide. Neuropeptides are small, protein-like chains of amino acids that neurons use to communicate with each other.[5] The mechanism of action of DSIP, however, remains unclear. Unlike many conventional sleep medications, DSIP does not appear to exert its effects through direct modification of major neurotransmitter systems responsible for sleep.[4] Instead, several hypotheses have been proposed based on preclinical investigations.

The earliest studies suggested that DSIP could selectively enhance delta-wave activity during NREM sleep.[1] Delta waves are low-frequency, high-amplitude brain oscillations that characterize slow-wave sleep, the deepest stage of NREM sleep associated with physical restoration, memory consolidation, and metabolic recovery. Investigators hypothesized that DSIP might facilitate the transition into or maintenance of these restorative sleep stages. However, findings have been inconsistent. Some studies demonstrated increased slow-wave sleep following DSIP administration, whereas others reported no significant differences compared with placebo.[3] Notably, one review suggested that certain structural analogues of DSIP, but not DSIP itself, showed significant slow-wave sleep-promoting activity in rabbits and rats.[3] Variations in species studied, routes of administration, dosing regimens, and experimental methodologies likely contributed to these conflicting results.

DSIP has also been implicated in the regulation of several endocrine pathways. Experimental studies suggest that the peptide may influence the secretion of hormones, and a possible mechanism of action involving the modulation of adrenergic transmission has been proposed.[4] Another area of interest involves DSIP's potential effects on the hypothalamic-pituitary-adrenal (HPA) axis, a key regulator of the physiological stress response. Animal studies have reported that DSIP administration may reduce certain hormonal responses to stress. For example, one study showed that DSIP reduced corticotropin-releasing factor (CRF)-stimulated corticosterone release in rats.[8] In humans, one study found that DSIP reduced circulating ACTH levels, while another found no effect on CRH-stimulated ACTH and cortisol secretion.[9,10] These conflicting results highlight the uncertainty that persists in this area of research. One of the greatest challenges in DSIP research has been the inability to identify a specific receptor through which the peptide consistently exerts its effects. Most biologically active peptides bind to well-characterized receptors that initiate defined signaling cascades. To date, no such receptor has been conclusively linked to DSIP, nor has a DSIP gene been identified.[3]

Conclusion

Delta sleep-inducing peptide represents an intriguing chapter in the history of sleep research. Since the initial investigations began in the 1960s, scientists have explored its possible roles in sleep regulation, stress adaptation, pain modulation, and neuroendocrine function. However, decades later, many questions remain unanswered. Although early findings generated enthusiasm regarding DSIP's potential therapeutic applications, the current body of evidence is limited and often conflicting. The DSIP gene, a precursor protein, and a specific receptor have never been identified, and its natural occurrence in the body remains debated. Larger, well-designed clinical trials are needed to clarify whether DSIP has a meaningful role in the management of sleep disorders or other health conditions. As our understanding of sleep biology continues to evolve, compounds such as DSIP remind us that promising scientific discoveries require careful investigation before they can be translated into safe and effective clinical therapies. Healthcare providers should be consulted before initiating any non-approved treatment.

‍